MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-07-2025
Exicure DSO Ratio 2011-2025 | XCUR
Annual DSO Ratio Exicure
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -4.16 | 0.242 | 76.3 | 40.2 | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 76.3 | -4.16 | 28.2 |
Quarterly DSO Ratio Exicure
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.5 | 7.17 | 0.41 | 0.21 | 0.13 | 4.71 | 2.77 | 2 | 5.47 | 395 | 59.2 | 52.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 395 | 0.13 | 44.2 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Arbutus Biopharma Corporation
ABUS
|
31.5 | $ 4.86 | 3.08 % | $ 807 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
6.01 | $ 3.22 | -1.08 % | $ 249 M |  USA |
 |
Aptevo Therapeutics
APVO
|
79 | $ 1.05 | -7.08 % | $ 290 K | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 0.27 | -4.88 % | $ 588 M |  Israel |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
Catalyst Biosciences
CBIO
|
3.24 | $ 13.58 | -3.62 % | $ 894 M | USA |
 |
Ascendis Pharma A/S
ASND
|
132 | $ 216.09 | -1.96 % | $ 5 B |  Danmark |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alterity Therapeutics Limited
ATHE
|
16.2 K | $ 3.14 | -4.15 % | $ 7.55 B |  Australia |
 |
Celldex Therapeutics
CLDX
|
86.5 | $ 27.1 | -1.51 % | $ 1.75 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
25.7 | $ 88.16 | 0.19 % | $ 9.1 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
44.2 | $ 24.27 | 2.75 % | $ 2.87 B | USA |
 |
CureVac N.V.
CVAC
|
13.6 | $ 5.02 | -0.59 % | $ 934 M |  Germany |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
25 | - | -15.15 % | $ 60.3 M | Britain |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
56.5 | $ 10.8 | - | $ 1.4 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
62.6 | $ 26.2 | 3.68 % | $ 1.27 B | USA |
 |
Anika Therapeutics
ANIK
|
77.3 | $ 9.57 | 0.1 % | $ 140 M | USA |
 |
Eton Pharmaceuticals
ETON
|
30.4 | $ 15.96 | -4.42 % | $ 409 M | USA |
 |
Evogene Ltd.
EVGN
|
30 | $ 1.07 | -0.51 % | $ 27.9 M | Israel |
 |
Exelixis
EXEL
|
45.1 | $ 41.43 | 1.35 % | $ 12 B | USA |
 |
Arena Pharmaceuticals
ARNA
|
946 | - | -6.81 % | $ 3.04 B | USA |
 |
Athersys
ATHX
|
22.6 | - | 3.77 % | $ 22.4 M | USA |
 |
Axon Enterprise
AXON
|
134 | $ 548.8 | -2.74 % | $ 41.6 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
150 | $ 2.39 | 3.91 % | $ 15 M | USA |
 |
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
254 | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
49.5 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
169 | $ 11.36 | -1.47 % | $ 735 M | USA |
 |
Biogen
BIIB
|
57.9 | $ 174.34 | 0.14 % | $ 25.4 B | USA |